LucyRx founder and CEO David Blair is recognized among The CEO Magazine’s Innovators 2026 honorees. His perspective highlights adaptability as an important leadership priority in a fast-changing pharmacy benefits market.
LucyRx and Abarca Health have completed their strategic combination, marking the transition from announced deal to completed transaction. The coverage highlights the combined organization’s scale, independent brands and continued client relationships across commercial and government markets.
LucyRx and Abarca Health have completed their strategic combination, bringing together capabilities across employer and payer markets. The coverage highlights the combined organization’s scale and the complementary expertise supporting commercial and government clients.
The growing overlap of GLP-1s, menopause, beauty and wellness raises important questions about clinical support and evidence. Employers evaluating women’s health benefits can consider how education and appropriate care pathways fit into this expanding landscape.
A real-world study examined the relationship between sustained Zepbound use and healthcare costs among adults 55 and older with obesity. The findings highlight why employers may consider longer-term costs alongside immediate GLP-1 therapy spending.
GLP-1 coverage decisions extend beyond the immediate cost of therapy. This feature examines the access, clinical, member support and value considerations employers should address when developing a GLP-1 strategy.
LucyRx and Abarca Health today announced the completion of their previously announced strategic combination.
LucyRx is expanding pharmacy access through a collaboration with Mark Cuban Cost Plus Drug Company, giving members more affordable prescription options while helping employers manage pharmacy costs.
As GLP-1 therapies expand beyond diabetes and weight loss, traditional employer coverage approaches can leave higher-risk members behind. This five-part Pharmaceutical Executive Q&A examines ways to expand access while keeping prescription benefit costs manageable.
Perimenopause and menopause can coincide with increased cardiovascular risk, yet some women face limited access to affordable GLP-1 treatment. This Q&A explores how employers can make more informed coverage decisions through targeted benefit design.